What the PEPFAR phase-out means for Namibia’s health budget
By Willem Kanyondi
Namibia has twelve months to convert a donor-funded programme into a domestically financed one. The exposure is not where most of the commentary has assumed it is.
On 4 September 2026, the United States and Namibia jointly announced that direct US financial assistance for Namibia’s HIV response will end after the 2027 fiscal year. Washington will provide approximately US$45 million for FY2027 as a transition, after which the relationship converts to technical cooperation only.
Over twenty-two years, PEPFAR has contributed roughly US$1.1 billion to the
Namibian HIV response.
The joint statement framed the decision as recognition of achievement, and on the metrics it is. Namibia has reached 96% of people living with HIV knowing their status, 98% of those diagnosed on treatment, and 98% of those treated virally suppressed — above the UNAIDS 95-95-95 benchmark for epidemic control.
The proximate trigger, however, was Namibia’s rejection of proposed US provisions on the sharing of health data and biological specimens, which the government declined on grounds of constitutional privacy protection and sovereignty over biological resources.
Zimbabwe, Ghana and Zambia have raised comparable objections; Kenya’s agreement is under court challenge.
For anyone working in health financing, the immediate question is not whether the decision was justified.
It is what the withdrawal actually costs, where the exposure sits, and what has to be built in the next twelve months. On all three, the public commentary has so far been imprecise.
What is actually being withdrawn
The most important fact in this story is one that has been widely under-reported:
Namibia already funds most of its antiretroviral treatment programme from the domestic budget. Free treatment reaches approximately 220,000 people, and the commodity cost of that treatment is largely a national obligation already.
What PEPFAR money has predominantly funded is different. In the Namibian context, it has supported community health workers, voluntary medical male circumcision, condom provision, and prevention programming targeted at adolescent girls and young women.
Tonata, a patient network representing around 29,000 people living with HIV, has been explicit that the immediate concern is the loss of support services — community adherence support, counselling and outreach — rather than the drugs themselves.
This distinction determines everything about the risk profile. The exposure is not primarily in treatment commodities. It is in prevention infrastructure and in the retention machinery that keeps 220,000 people adherent month after month.
That machinery is inexpensive relative to treatment, and it is precisely what produces the 96-98-98 result the withdrawal was justified by.
The fiscal arithmetic
At prevailing exchange rates, US$45 million is in the order of N$800 million annually. This is a recurrent obligation, not a one-off, and it arrives into a health envelope already absorbing two significant commitments: the public-sector expansion under Vision April 2026, including more than 2,000 funded health posts, and the operational consequences of the state-facility tariff realignment approved by Cabinet in May.
Three features of this gap matter for budgeting.
The window is twelve months, not several years. FY2027 funding is transitional by design. A domestic line item has to be secured in the next budget cycle.
Treating this as a problem for the 2028 medium-term expenditure framework would mean the gap arrives before the provision does.
The displacement question is unavoidable. Absorbing N$800 million into the
MOHSS vote without new revenue means reallocating from elsewhere — tuberculosis programming, maternal health, infrastructure — or expanding the health envelope against competing claims. This is the same fiscal-space constraint that has kept the National Medical Benefit Fund unimplemented since 1994.
It now has a concrete number attached to it, which is arguably useful: abstract fiscal space arguments are easy to defer, specific ones less so.
The regional fallback has closed. The United States has announced the phaseout of more than US$400 million annually for South Africa’s HIV programmes and a broader phased PEPFAR drawdown.
Regional cost-sharing or donor substitution from neighbouring programmes is not available, because the neighbours are managing the same withdrawal simultaneously.
The retention risk, in financial terms
The 96-98-98 achievement is a stock measure, not a permanent condition. Viral suppression across 220,000 people is maintained continuously, through adherence support, defaulter tracing, counselling and community outreach — the same components most exposed by the withdrawal.
The financial logic of allowing that infrastructure to erode is poor, and it is worth stating in cost terms rather than public-health terms.
A patient who disengages from care and experiences treatment failure moves onto second-line and eventually third-line regimens, which are substantially more expensive per patient-year than first-line therapy.
Treatment interruption raises the incidence of opportunistic infections, which present as inpatient admissions — the most expensive setting in any health system.
Loss of viral suppression at population scale raises onward transmission, which expands the treatment cohort itself, permanently.
In other words, the cheapest component of the programme is the one whose loss generates the most expensive downstream consequences. Any absorption strategy that protects commodity procurement while allowing community and retention services to lapse would be optimising the wrong variable.
The sovereignty trade-off, stated plainly
It should be said directly that this outcome followed a deliberate policy choice.
Namibia declined the data- and specimen-sharing provisions on constitutional and sovereignty grounds, and the consequence is the loss of approximately N$800 million a year in external support.
Reasonable people will assess that trade-off differently, and it is not the purpose of this analysis to adjudicate it.
What is relevant to health financing is the principle it establishes. Namibia has now demonstrated that it will accept fiscal cost to retain control over health data and biological resources.
If that principle is to be more than a one-off assertion, it has to be matched by a financing model capable of sustaining the programmes concerned without the external funding that was declined. Sovereignty over health data implies responsibility for health financing.
The two propositions are inseparable, and the next twelve months will test whether the second has been thought through as carefully as the first.
There is also a longer-run argument in Namibia’s favour here. A programme dependent on annual external appropriation is exposed to the politics of another country’s budget cycle, as the funding pause of early 2025 demonstrated across the region.
Domestic financing is more expensive in the short term and more secure in the long term. The transition being forced now is one that would have had to happen eventually.
Why this concerns the private sector and the funds
Medical aid funds and private providers may reasonably regard this as a publicsector problem. That reading is incomplete, for three reasons.
Downstream acute demand is shared. Deterioration in public-sector HIV outcomes produces patients presenting later, sicker, and with advanced disease.
A proportion of those patients are insured, and they present at private facilities.
Advanced HIV disease admissions are high-acuity and high-cost, and they land in fund claims experience.
Budget displacement affects the whole system. If N$800 million is absorbed by reallocation rather than new revenue, the programmes that lose funding are elsewhere in the health system.
The consequences — in tuberculosis control, maternal outcomes, or facility capacity — do not respect the boundary between public and private financing.
The workplace exposure is direct. Prevention programming that PEPFAR funded operated at community and workplace level.
Employers and the funds that cover their employees have a measurable interest in prevention continuing,because the alternative appears eventually as claims.
What can practically be done
The following are grounded in structures Namibia already has, rather than institutions it would need to create.
Use the transition year to build the line item, not to defer it. The single highest-value action available in the next twelve months is a costed disaggregation of what PEPFAR actually funds in Namibia — by component, by implementing partner, by district — so that the domestic budget provision is built against real numbers rather than an aggregate.
Much of this data exists in PEPFAR country operational planning documentation and in MOHSS programme records. It has to be consolidated into a form the Ministry of Finance can appropriate against.
Protect the retention infrastructure first, explicitly. Given the cost asymmetry described above, community health workers, adherence support and defaulter tracing should be ring-fenced as the first call on domestic absorption, ahead of components with weaker downstream cost consequences. This is a sequencing decision that can be made now and costs nothing to decide.
Retain the trained workforce by transferring the payroll. PEPFAR’s most durable investment in Namibia is a trained community health workforce. That workforce exists, is experienced, and is embedded in communities.
Absorbing those positions into the MOHSS establishment — rather than allowing the cadre to disperse and rebuilding it later — is substantially cheaper than reconstruction, and it is an operational decision within the Ministry’s control.
Integrate rather than run parallel. HIV services in Namibia, as in most PEPFAR countries, have operated with significant vertical programme architecture — separate reporting, separate supply chains, separate management.
Full integration into general primary health care, which the joint statement itself anticipates, removes duplicated overhead.
Integration is not merely a policy aspiration here; it is one of the few genuine efficiency savings available at the scale required.
Optimise the remaining multilateral relationships. The Global Fund to Fight AIDS, Tuberculosis and Malaria remains an active financing channel and operates on a different basis from bilateral US assistance.
Its allocation cycles and co-financing requirements reward countries that demonstrate increasing domestic commitment — which is precisely the position Namibia will be in.
This will not replace US$45 million, but it is the most immediately available partial offset.
Broaden the domestic revenue base rather than reallocating within health.
Namibia is not without options here, and several are already under discussion in the context of the National Medical Benefit Fund: dedicated levies on telecommunications turnover, on regulated insurers’ premiums, or on specified fee and fine revenue.
Rwanda’s community health insurance now draws on precisely this kind of diversified base.
A dedicated health financing revenue line would serve both the immediate HIV absorption and the longer-term UHC architecture, and building one instrument for both purposes is more efficient than building two.
Recover what is already being lost to leakage. PSEMAS has documented exposure to fraud, false claims and beneficiary irregularity.
Rigorous claims verification and recovery in the public scheme is not a substitute for new revenue, but it is money already appropriated to health that is not currently buying health services.
In a year when N$800 million has to be found, recovery of existing leakage is the least politically costly source available.
Bring the funds and employers into prevention formally. Workplace HIV prevention and testing programmes were substantially donor-funded.
Medical aid funds and large employers have a direct financial interest in their continuation. A structured public-private prevention compact — with NAMAF and the larger employers — would cost the fiscus little and preserve programming that would otherwise lapse entirely.
The bottom line
Namibia is being asked to convert a twenty-two-year donor relationship into a domestic budget line in twelve months, having achieved the epidemic control that made the withdrawal possible, and having accepted the fiscal consequence of a sovereignty decision it took deliberately.
The exposure is narrower than the headline number suggests, because treatment is already substantially domestically funded.
But it is concentrated in exactly the components — retention, adherence, prevention — whose loss would be most expensive to reverse.
The financing question is therefore not simply whether N$800 million can be found. It is whether it can be found in a form that protects the cheap infrastructure producing the expensive outcome.
Twelve months is enough time to build a costed, sequenced absorption plan. It is not enough time to build one after the funding has stopped.
*Willem Kanyondi is a nurse practitioner turned clinical auditor and CIMA candidate, specialising in healthcare revenue integrity and risk. He writes on the intersection of clinical operations, financial management and healthcare financing. He writes here in his personal capacity.
